Ranolazine Prevents Cardiac Remodeling in HCM
progression toward end-stage heart failure, 6 when compared with the more common thick-filament mutation carriers.
To date, however, when a young individual is diagnosed with having a high-risk HCM-associated mutation, clinicians can only suggest a close follow-up strategy, for lack of robust therapeutic options capable of delaying or preventing disease onset and progression. 1 Although gene therapy still seems distant and likely reserved to selected genotypes, an attractive alternative is represented by disease-modifying drugs interfering with the subcellular and cellular mechanisms of myocardial adverse remodeling. 7 A growing number of preclinical studies have identified changes in intracellular Ca 2+ handling as fundamental determinants of electromechanical dysfunction in HCM myocardium, both in transgenic animal models 8, 9 and in human ventricular cardiomyocytes. 10 Indeed, elevated intracellular Ca 2+ levels are associated with increased activation of cardiac Ca 2+ -calmodulin-dependent protein kinase (CaMKII), a key player of adverse cellular remodeling in human HCM. 10 HCM-related abnormalities of Ca 2+ homeostasis seem to occur independently of the underlying mutation, thus, representing an ideal universal target.
Of note, previous studies pointed out that long-term reduction of intracellular Ca 2+ overload with the Ca 2+ channel blocker diltiazem is capable of delaying and mitigating phenotype expression in HCM mouse models. 11 Following these observations, a pilot clinical study has been performed in which nonhypertrophic mutation carriers exhibiting initial diastolic abnormalities were treated with diltiazem. The results of the study revealed that early treatment with diltiazem does delay the development of diastolic dysfunction in carriers. 12 However, the study duration was too short to measure a significant effect on the development of hypertrophy. 12 Furthermore, diltiazem is not the ideal drug in young asymptomatic patients because of potential occurrence of bradycardia, hypotension, and exercise intolerance. 12 Nevertheless, these observations are consistent with the idea that an early and sustained reduction in intracellular Ca 2+ may slow the natural progression of disease phenotype.
An alternative therapeutic option to reduce intracellular Ca 2+ overload in HCM is pharmacological inhibition of the late Na + current (I NaL ) using the clinically available, prototypical inhibitor ranolazine. I NaL is pathologically increased in human HCM, causing intracellular Ca 2+ accumulation. 10 Studies performed on human HCM cardiomyocytes showed that after I NaL inhibition, reduction of action potential (AP) duration (APD) leads to decreased Ca 2+ entry, while normalization of intracellular Na + potentiates Ca 2+ extrusion from the cytosol via the Na-Ca exchanger (NCX), 10 ultimately causing a reduction of both [Ca 2+ ] and CaMKII activity. 13 Based on these findings, we sought to determine whether I NaL inhibition with ranolazine affects long-term disease progression in HCM. Toward this goal, transgenic mice carrying the HCM-related R92Q mutation in the troponin-T (TnT) gene 14 were subjected to a lifelong oral treatment with ranolazine and compared with vehicle-fed animals. Results of the present study showed that long-term treatment with ranolazine counters the development of HCM-related cardiac remodeling and prevents myocardial dysfunction in mutant mice.
Materials and Methods
Detailed methods are available in the Data Supplement. All experimental protocols were performed in accordance with current Italian and European regulations and were approved by the local institutional review board and by the animal welfare committee of the Italian Ministry of Health. We used male C57BL/6N knock-in mice carrying the R92Q mutation in the TnT gene (R92Q mice), 14, 15 as well as wild-type (WT) littermates. Each litter was randomized to treatment with chow containing 0.5% ranolazine and 0.03% ketoconazole (RAN group) or ketoconazole only (KET group), starting 1 to 2 days after birth. Treatment was continued till 11 to 12 months of age when mice were used for the following experiments. Ranolazine plasma concentration at the time of killing was measured with liquid chromatography analysis coupled with tandem mass spectrometry. Echocardiography was performed on anesthetized mice as previously described 16 to characterize LV morphology and systolic and diastolic function. Cardiac magnetic resonance was performed as previously described 17 to asses LV and right ventricular volumes and mass, as well as to calculate the fraction of extracellular space by studying the decay of contrast signal after intravenous gadolinium compound infusion. 18 Single cardiomyocytes were isolated from excised hearts via enzymatic dissociation and used for intracellular Ca 2+ measurements using Ca-sensitive fluorescent dyes 19, 20 ] was performed after staining single cells with Fura-2 and Natrium Green-2. Patch-clamp studies were performed to record APs and I NaL in single LV cardiomyocytes. To assess T-tubule density, myocytes were stained with membrane-selective dyes and observed with a confocal microscope. 19 Formalin-fixed LV slices were stained with picrosirius red and used to assess intramyocardial fibrosis. Fast-frozen LV myocardial samples were processed to obtain total proteins, which were used for Western blot studies to assess the expression and phosphorylation of CaMKII and other proteins involved in excitation-contraction coupling. 21 LV and right ventricular intact trabeculae were dissected from explanted hearts 20, 22 and used to record isometric force during electric stimulation with different pacing protocols, aimed at evaluating twitch amplitude and kinetics, response to high-frequency pacing, prolonged pauses, as well as the effects of β-adrenergic activation. 19 Skinned trabeculae were used to obtain force-pCa curves by transferring them manually between baths containing different pCa solutions, as previously described. 23 Data from cells and muscles are expressed as mean±SEM (number of samples and animals are indicated in the respective figure legends). Statistical analysis was performed as previously described 21 using SPSS 23.0 (IBM) and STATA 12.0 (StataCorp). In brief, all sets of variables were checked for normality (Shapiro-Wilk test) and for homogeneity of variances among groups (Levene's Test). The statistical tests used to calculate P values for each data set are indicated with abbreviations in the respective figure legends. For variables where a single measurement for each mouse is included (eg, echocardiography, Western blot), the 3 different groups were compared using (1) 1-way analysis of variance with Tukey correction (for normally distributed homoscedastic data sets), (2) Kruskal-Wallis test with Dunn's multiple comparison test (for non-Gaussian data sets) or (3) Welch's analysis of variance with Games-Howell test (for heteroscedastic groups). For variables where measurements from an unequal number of different samples (eg, cells or trabeculae) from each mouse are included (pathclamp, ion fluorescence, isometric force data), we used linear mixed models to compare data groups to account for intrasubject correlation; when comparing >2 groups, the Tukey-Kramer post hoc method was used to compute P values for all pairwise comparisons. P<0.05 was considered statistically significant.
Results

Rationale for Using Ranolazine in R92Q Mice
We first sought to determine whether and how acute ranolazine administration exerts beneficial effects in the myocardium of Ranolazine Prevents Cardiac Remodeling in HCM R92Q mutant mice. LV cardiomyocytes were isolated from the hearts of R92Q and WT male mice aged 4 to 6 months and used for patch-clamp experiments to record I NaL and APs in the absence and presence of 10 μM ranolazine. I NaL density was 2-fold higher in cardiomyocytes from R92Q as compared with those from WT cells. In mutant cardiomyocytes, ranolazine reduced I NaL down to the level of that in WT cells ( Figure 1A and 1B). Accordingly, ranolazine administration led to a reduction of APD in R92Q cardiomyocytes at all investigated frequencies, while it did not affect APD in WT cells (Figure 1C and 1D) . Interestingly, I NaL was already increased in cardiomyocytes from R92Q mice at 1 month of age, as compared with cells from age-matched WT mice ( Figure IA in the Data Supplement), suggesting that the increase of I NaL occurs early during disease development in this model. In line with previous reports, 24 ranolazine (10 μM) shows use-dependent block of I NaL , with no significant effects on peak Na + current ( Figure IB and IC in the Data Supplement).
We then studied the effects of I NaL inhibition on intracellular [Na + ] and [Ca 2+ ] by simultaneously monitoring the concentration of the 2 ions in R92Q and WT cardiomyocytes costained with the ion-sensitive fluorescent dyes Asante Natrium Green and Fura-2 (for Na + and Ca
2+
, respectively). Cardiomyocytes were field-stimulated at increasing rates (1) (2) (3) (4) (5) (6) (7) 
Long-Term Treatment Protocol
To test whether ranolazine is effective in slowing or preventing the development of the pathological phenotype in mutant mice, male animals carrying the R92Q TnT mutation and WT littermates received an oral treatment with ranolazine since birth and were compared with age-matched vehicle-treated siblings. A detailed scheme of the experimental protocol is shown in Figure II in the Data Supplement. Male R92Q animals were fed with chow containing 0.5% ranolazine+0.03% ketoconazole (RAN treatment). Ketoconazole was added to inhibit hepatic CYP3A4 to maintain ranolazine plasma concentration within the range of 2 to 8 μmol/L throughout the day, values comparable to therapeutic levels in humans ( Figure III in the Data Supplement). RAN-treated animals were compared with age-matched R92Q animals fed with chow containing only 0.03% ketoconazole (KET treatment). R92Q heterozygous mice were mated with WT females to obtain mixed litters. Treatment was started immediately after birth; each litter was assigned randomly to RAN or KET treatment group. Survival analysis did not show any difference among WT-KET, WT-RAN, R92Q-KET, and R92Q-RAN groups: the number of animal who died during the 12 months of treatment was low and comparable in the 4 groups (WT-KET=1/23, WT-RAN=1/22; R92Q-KET=2/22; R92Q-RAN=2/23; P>0.05 at χ 2 test for all comparisons). No differences were noted between WT-KET and WT-RAN mice in terms of gross cardiac structure and function as evaluated with a specific subset of in vivo assessments (Table I in the Data Supplement). Therefore, WT-RAN mice were used as a single control group throughout the study (henceforth named WT). All animals were treated for 12 months and then used in the experiments described below. Average ranolazine concentration measured in plasma at killing was 4.41±1.01 μmol/L (mean±SE from 15 animals).
Echocardiography
Before echo assessments, heart rate and arterial blood pressure were measured in conscious mice: no differences were noted in the basal vital parameters among the 3 groups of animals (Table II in the Data Supplement). Echocardiographic acquisitions were performed in anesthetized 12-month-old male mice from the 3 study groups (11 WT, 11 R92Q-KET, and 11 R92Q-RAN) using a standardized protocol 25 ; measurements were performed offline in a blind manner.
Lifelong ranolazine treatment fully prevented the development of structural LV changes in R92Q mutation carrier mice ( Figure 2 ). The increase in interventricular septum thickness, a hallmark of HCM remodeling, was not present in ranolazine-treated mice, as evaluated from long-axis parasternal views (Figure 2A and 2C) . Three short-axis views ( Figure 2B ) at different levels of the LV were used to estimate chamber volumes. A reduction in end-diastolic and end-systolic LV volumes, although present in all vehicle-treated mutants, was entirely prevented in R92Q-RAN mice ( Figure 2D ). LV hypercontractility was documented in R92Q-KET animals by an increased ejection fraction (LV ejection fraction) and an augmented fractional increase of septal thickness during contraction, as compared with WT. Remarkably, LV hypercontractility was absent in ranolazine-treated mice ( Figure 2E ). No differences were noted in terms of stroke volume, cardiac output, and heart rate among the 3 groups of animals (Table III in the Data Supplement).
Doppler studies of transmitral blood flow ( Figure 3A ) and measurements of left atrial (LA) dimensions ( Figure 3C ) were performed in 4-chamber views to assess diastolic function. Reduced transmitral blood flow during early diastole (ie, reduced E wave amplitude) paralleled by an increased proportion of LV diastolic filling relying on atrial contraction (ie, increased A wave amplitude) is found to be consistent with impaired ventricular relaxation. LA size may increase because of elevated LV filling pressure. E/A ratio was markedly lower, Figure 3D) , and E/A ratio was significantly higher than that in R92Q-KET mice, though it was still lower than that in WT mice ( Figure 3B ).
Increased productions of ANP (atrial natriuretic peptide) and BNP (brain natriuretic peptide) from atrial and ventricular tissue are markers of the increased chamber filling pressures in the setting of diastolic dysfunction. 25 Ranolazine treatment counteracted the increase in mRNA expression of both ANP-and BNP-coding genes (Table IV in the Data Supplement), in line with the prevention of diastolic abnormalities.
Cardiac Magnetic Resonance
A total of 8 WT, 8 R92Q-KET, and 8 R92Q-RAN mice underwent cardiac magnetic resonance tests performed using a 7-Tesla scanner (Bruker Pharmascan) optimized for small 17 to measure chamber volumes and wall mass from sequential short-axis sections ( Figure 4A ). Consistent with the echocardiographic data, ranolazine prevented the reduction of LV end-diastolic volume and the increase of septal wall thickness and LV ejection fraction, which were observed in all untreated mutant mice ( Figure 4B ). Total LV wall mass was unchanged in R92Q-KET versus WT mice and was unaffected by ranolazine treatment ( Figure 4B ).
A gadolinium compound was administered intravenously, and the decay of gadolinium contrast intensity in LV myocardium was used to estimate the fraction of extracellular space as an index of the interstitial fibrosis 18 ( Figure 4C ). Ranolazine treatment significantly prevented the pathological expansion of extracellular volume in R92Q mutant mice ( Figure 4D ).
Histology and Confocal Imaging
Formalin-fixed LV samples were embedded in paraffin, and thin sections were stained with picrosirius red to highlight myocardial collagen fibers ( Figure 5A ). Analysis of stained sections from 5 animals from each of the 3 groups confirmed that lifelong ranolazine treatment counteracted the increase of myocardial collagen in R92Q mice ( Figure 5B), in line with contrast magnetic resonance imaging data ( Figure 4D ). Myocardial fibrosis in cardiac diseases is subtended by increased local synthesis of transforming growth factor β. 26 Consistent with histological and magnetic resonance imaging data, ranolazine treatment prevented the increase in transforming growth factor β expression seen in R92Q mutants (Table IV in the Data Supplement). Freshly isolated mouse LV cardiomyocytes were stained with membrane-selective fluorescent dye di-3-aneppdhq (Life Technologies) and were then observed with a confocal microscope ( Figure 5C ) to assess the structure and organization of the T-tubular system. 22, 27 The density of T-tubules and mean sarcomere length were then quantified using fast Fourier transform as previously described. 27 Ranolazine treatment partially prevented the reduction of the density and the impairment of the organization of T-tubules (TTPower parameter; Figure 5D ) that were much more marked in cells from untreated R92Q mice. Of note, resting sarcomere length, which was significantly reduced in untreated R92Q cardiomyocytes, was the same in R92Q-RAN and WT cells ( Figure 5E ).
Intracellular Ca 2+ Handling in Single Cardiomyocytes
All experiments in cells and trabeculae were performed using experimental solutions devoid of ranolazine. Intracellular Ca 2+ measurements were performed in isolated cardiomyocytes during electric field stimulation at 3 different frequencies (1, 3, and 5 Hz). Figure 6 shows that ranolazine treatment prevented the alterations of Ca 2+ handling Figure 6A and 6D ). In keeping with these observations, the reduction of Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase type 2a (SERCA2a) protein and mRNA-expression of ATP2a2 gene, found in R92Q-KET hearts, was abolished in R92Q-RAN hearts (Table IV in the Data Supplement); this is likely to have contributed to the faster Ca 2+ transient kinetics observed in R92Q-RAN versus R92Q-KET cardiomyocytes.
Cardiomyocytes were rapidly exposed to 10 mmol/L caffeine after 30 s of conditioning stimulation at 1 Hz ( Figure 6E ) to estimate total sarcoplasmic reticulum Ca 2+ content and study the rate of Ca 2+ extrusion from the cytosol via the NCX. The amplitude of caffeine-induced Ca 2+ transients was similar in WT and R92Q-KET cardiomyocytes and was not modified by treatment with ranolazine ( Figure 6E ), suggesting that no major changes in sarcoplasmic reticulum Ca 2+ content occur in this disease model at 12 months of age. However, the drug prevented the slowing of the decay rate of caffeine-induced Ca 2+ transients, suggesting that the rate of Ca 2+ extrusion via the NCX is normalized in R92Q-RAN cardiomyocytes ( Figure 6F) . Interestingly, the mRNA expression of the NCX gene was similar in the 3 study groups (Table IV in Fast-frozen LV myocardial samples from R92Q, R92Q-RAN, and WT animals (8 per group) were processed to obtain total proteins, which were used for Western blot studies ( Figure 6G and 6H), as previously described. 10 CaMKII autophosphorylation, a marker of CaMKII activation, was increased in R92Q hearts as compared with that in WT mice. In ranolazinetreated R92Q mice, instead, the increase of CaMKII autophosphorylation was fully prevented. In agreement with this observation, ranolazine treatment prevented the increase of the phosphorylation of specific CaMKII target site on phospholamban. Additionally, ranolazine treatment prevented the reduction of total SERCA and phospholamban (PLB) proteins in R92Q mutant hearts. Phosphorylation of protein kinase A targets was similar in WT and R92Q hearts and remained unchanged by treatment ( Figure IV in the Data Supplement). Finally, ryanodine receptor's total protein amount and phosphorylation levels were found to be similar in the 3 groups ( Figure IV in the Data Supplement).
Arrhythmogenic Ca 2+ Release
We then assessed the rate of intracellular Ca 2+ waves and spontaneous Ca 2+ transients occurring during pauses. Toward this goal, cardiomyocytes were stimulated at 5 Hz, and pacing was abruptly stopped for 20 s, in the absence and presence of isoproterenol 10 -7 mol/L ( Figure 7A ). Treatment with release seen in untreated R92Q cardiomyocytes. Indeed, the frequencies of spontaneous Ca 2+ waves and Ca 2+ transients in cells from R92Q-RAN mice were markedly reduced compared with those from R92Q-KET mice, both at baseline and during β-adrenergic stimulation ( Figure 7A and 7B) , that is, they were in the range of those observed in cardiomyocytes from WT mice.
Mechanical Function in Ventricular Trabeculae
Isometric force was measured from LV and right ventricular trabeculae or thin papillary muscles during field stimulation with different pacing protocols ( Figure 8A and 8F) . The response to stimulation frequencies (0.1-6 Hz) and the effects of β-adrenergic stimulation were evaluated, as well as the occurrence of spontaneous contractions during prolonged pauses ( Figure 8B through 8G) . Ranolazine treatment restored the positive inotropic responses that were markedly blunted in R92Q myocardium. In R92Q-KET trabeculae, we observed a significant reduction of twitch tension compared with that in WT, both at fast pacing rates (≥3 Hz) and in response to isoproterenol, while the positive inotropic effects in response to fast stimulation and isoproterenol in R92Q-RAN muscles were similar to those of WT ( Figure 8B and 8C) . Ranolazine treatment markedly mitigated the frequency-dependent increase of diastolic tension in R92Q trabeculae ( Figure 8D) . Moreover, the kinetics of contraction and relaxation at low pacing frequencies (0.1-1 Hz) were faster in R92Q-RAN trabeculae, as compared with those in vehicle-treated mutants ( Figure 8E) . Ranolazine, however, did not prevent the prolongation of twitch relaxation at higher frequencies (>1 Hz). Interestingly, treatment reduced the occurrence of spontaneous contractions during pauses to values similar to those observed in WT trabeculae ( Figure 8F ), a finding consistent with the reduction of intracellular Ca 2+ waves and Ca 2+ transients detected in isolated cardiomyocytes from R92Q-RAN hearts.
Finally, as previously reported 23 the R92Q cTnT mutation is associated with a marked increase in myofilament Ca 2+ sensitivity that was assessed in skinned ventricular trabeculae ( Figure 8G ). Ranolazine treatment did not affect the increase in myofilament Ca 2+ sensitivity associated with the mutation. The pCa50 of force generation was higher in both untreated and treated R92Q skinned preparations versus WT and was similar in R92Q-KET and R92Q-RAN mice.
Discussion
R92Q-TnT Mouse Recapitulates the Main Features of Human HCM
In this work, we used a comprehensive, multilevel approach (from single cells to the whole heart) to demonstrate that the I NaL blocker ranolazine slows and attenuates the development and progression of morphological and functional HCM phenotypes in mutant mice carrying the R92Q mutation in the cardiac TnT gene.
The mouse model we used in this study 14 recapitulates the main pathophysiological features of HCM in patients, both at whole heart and single cardiomyocyte level. In (Figure 6 ). Interestingly, increased I NaL was a major contributor to the observed alterations of intracellular Ca 2+ handling in R92Q cardiomyocytes. All these functional cellular abnormalities are qualitatively similar to those we previously observed in human HCM cardiomyocytes. 10 The only remarkable difference between the R92Q mouse model and the human HCM cells is the absence of a prolonged ventricular AP in mouse myocytes, despite the observed increase of I NaL . On the contrary, when the excess of I NaL is inhibited by ranolazine, APD is significantly shorter in R92Q cardiomyocytes, as compared with WT cells. Previous work provided a possible explanation for this observation. 28, 29 In a transgenic mouse model carrying the I79N mutation of cTnT (whose effects on sarcomeric function are similar to R92Q), the higher myofilament Ca sensitivity, by increasing the total cytosolic Ca-buffering capacity of the cardiomyocyte, led to lower Ca-transient amplitude. The reduced size of Ca 2+ transients in I79N myocytes (as in R92Q cells, see Figure 6D and Supplementary Figure I in the Data Supplement), led to partial suppression of the Ca2 + extrusion mode of the exchanger, thereby, resulting in a smaller inward NCX-mediated current (I NCX ) during the repolarization phase, ultimately leading to shorter APD in mutant myocytes. An additional possible mechanism leading to AP shortening in R92Q cells is the activation of I K,ATP channels because of reduction of ATP concentration caused by the reduced energy efficiency of mutant myocardium. 15 In addition to the functional cellular abnormalities, the R92Q transgenic line showed a marked increase in endomyocardial fibrosis (Figures 4 and 5) , a hallmark of HCM in patients, particularly in those carrying thin-filament gene mutations. 6 Finally, a clear propensity to develop ventricular arrhythmias in response to adrenergic stimulation has been previously shown in this transgenic line 30 and was confirmed by our studies in single cells and intact trabeculae (Figures 7 and 8) . The functional and structural remodeling of mutant myocardium was associated with increased activation of CaMKII, a nodal protein in the regulation of cardiac physiology and pathology, whose enhanced activity is notably associated with cardiac hypertrophy and heart failure. 31 Interestingly, a similar increase in the phosphorylation of CaMKII and its downstream targets was also consistently found in cardiac samples from HCM patients. 21 Of note, despite an increased septal thickness measured with echo and magnetic resonance imaging, total LV wall mass was similar in R92Q versus WT hearts, in line with earlier findings in mice from this lineage.
14 HCM in patients is diagnosed in the presence of a maximal LV diastolic thickness >15 mm and not by the presence of an increased LV total mass. 2 Indeed, regional distribution of hypertrophy is common in HCM patients, and >35% of them show no or mild increase of total LV mass. 32 Moreover, the absence of global LV hypertrophy and the restrictive physiology, far from representing a limitation of this model, are typical of thin-filament HCM and are often observed in patients carrying similar high-risk mutations. 5, 6 All in all, the cardiac pathological phenotype observed in R92Q transgenic mice provides a better approximation of the wide spectrum of myocardial and cellular abnormalities observed in human pathology, as compared with other currently available HCM mouse models carrying mutations in Myosin Heavy Chain 11 or Myosin-binding Protein-C (MyBPC ), 33 increasing the translational value of our study.
Rationale for the Use of Ranolazine as a DiseaseModifying Strategy
The choice of ranolazine as a lifelong preventive treatment was driven by the positive acute effects that this drug exerted in cells and trabeculae isolated from patients with HCM 10 and by its safety profile and tolerability in patients. The mechanisms by which ranolazine is capable of normalizing intracellular Ca 2+ are directly related to its effect to inhibit cardiac I NaL . LV cardiomyocytes from R92Q hearts show a significantly increased density of I NaL when compared with WT cells (Figure 1) ; interestingly, the increase of I NaL is an early feature of cellular remodeling in R92Q myocardium, as it is already present in cells from 1-month-old mutant mice. Early hyperactivation of CaMKII (because of the onset of intracellular Ca 2+ overload) increases the phosphorylation of NaV1.5 channels at specific sites determining impaired current inactivation and may, thus, be the cause of the early increase of I NaL 34 in mutant hearts. Indeed, increased intracellular [Ca 2+ ] is widely considered among the first common consequences of HCM-causing sarcomeric mutations. Increased myofilament Ca 2+ sensitivity (Figure 8 ) leads to increased diastolic [Ca 2+ ] as a consequence of the larger cytosolic Ca-buffering capacity. 28, 29 The increased ATP consumption by the mutant sarcomere 15, 35 may reduce the amount of ATP available to fuel SERCA-mediated Ca-reuptake into the sarcoplasmic reticulum, ultimately contributing to cytosolic Ca 2+ overload, the main determinant of CaMKII activation and pathological I NaL enhancement.
The increased I NaL results into a marked intracellular Na + accumulation, especially at high pacing rates (Figure 1 ), which in turn contributes to increase intracellular diastolic [Ca 2+ ] by impairing the forward function of the NCX ( Figure 6 ). As in human HCM, 10 acute exposure to ranolazine, that markedly inhibited I NaL , reduced both intracellular [Na + ] and diastolic [Ca 2+ ] in R92Q cardiomyocytes (Figure 1 ). The normalization of diastolic Ca 2+ by ranolazine highlights the possibility of additional benefits in the long-term administration because increased diastolic Ca 2+ accumulation is one of the main subcellular determinants of myocardial adverse remodeling and disease progressions in animal models of HCM irrespective of genotype. 11, 36 Long-term treatment with ranolazine was effective in reducing the magnitude of cellular remodeling in other models of hypertrophy. 37, 38 In spontaneously hypertensive rats, chronic ranolazine treatment started before Ranolazine Prevents Cardiac Remodeling in HCM the onset of hypertrophy prevented the development of T-tubules disruption and significantly attenuated the degree of alterations of Ca 2+ handling. 37 In a model of deoxycorticosterone acetate salt-induced hypertension in rats, ranolazine treatment prevented the development of secondary modifications of the myocardial contractile apparatus, thus, reducing the severity of diastolic dysfunction. 38 However, long-term treatment with ranolazine has not been previously attempted in models of genetic heart disease.
Lifelong Ranolazine Treatment Prevents the Development of Diastolic and Systolic Dysfunction
In the present work, transgenic mice carrying the R92Q mutation of TnT were treated with ranolazine since birth and proved safe in this setting. Early initiation of treatment is likely essential because HCM-related alterations of myocardial structure and function are thought to develop early in life, possibly starting in the prenatal phase.
9,39 Ranolazine treatment effectively countered the development of diastolic dysfunction in our HCM mice, as evaluated by Doppler echocardiography ( Figure 3 ); in keeping with the improved diastolic function, a lower diastolic tension was observed in trabeculae from treated mice (Figure 8 ). The effect of the treatment on diastolic function was associated with the prevention of pathological Excitation-Contractioncoupling changes: myocytes from treated R92Q mice lacked the increase in diastolic Ca 2+ seen in vehicle-treated mice and showed a faster decay rate in Ca 2+ transient because of maintained near-normal SERCA and NCX function. Preservation of SERCA function seems particularly relevant to the outcome of ranolazine treatment; indeed, SERCA overexpression via gene transfer was capable of reducing phenotypic expression and disease progression in a murine model of HCM carrying a tropomyosin mutation. 36 Although abnormalities of Ca 2+ transient kinetics were fully prevented in R92Q-RAN cardiomyocytes, the prolongation of twitch relaxation kinetics was not entirely prevented in trabeculae from ranolazine-treated mice. The interplay between Ca 2+ removal from the cytosol and the intrinsic ability of myofilaments to switch off contraction contributes to determine the velocity of twitch relaxation. In line with previous studies, 14 skinned muscle from R92Q mice exhibited increased Ca 2+ sensitivity (Figure 8 ). Because this feature is a direct consequence of the mutation altering the thin-filament structure 40 and occurs upstream from the site of action of ranolazine, it was not surprising that Ca 2+ sensitivity was not affected by the treatment. Notably, this rules out any effect of ranolazine on transgene expression. The persistence of sarcomeric abnormalities explains why altered contraction kinetics are still present in R92Q-RAN myocardium, despite the normalization of intracellular Ca 2+ dynamics.
The link between fibrosis and diastolic impairment is critically relevant for the pathophysiology of HCM, particularly for thin-filament mutations. 6 Treatment with spironolactone (an aldosterone receptor blocker) and N-acetyl-cysteine (an antioxidant) attenuated fibrosis in transgenic mice carrying the R92Q-TnT mutation, and the reduction of fibrosis alone led to improvement in diastolic function. 41, 42 It is, therefore, notable that ranolazine treatment counteracted the expansion of extracellular volume in the ventricular myocardium of R92Q mice, as evaluated with contrast magnetic resonance imaging, reduced the proliferation of intramyocardial fibrosis in histological sections (Figures 4 and 5) , and prevented the increase of transforming growth factor β expression.
In addition to preventing diastolic dysfunction, lifelong ranolazine treatment also prevented the development of systolic abnormalities and rescued the blunted inotropic responses in mutant mice. Ventricular trabeculae from R92Q mice showed a slight reduction in twitch amplitude under baseline conditions but displayed significantly reduced responses to a variety of positive inotropic challenges mimicking exercise conditions, including high-frequency stimulation and β-adrenergic activation with isoproterenol. The reduction of inotropic reserve in R92Q mice was completely abolished by ranolazine (Figure 8 ). The clinical relevance of this effect is also important because progression toward systolic dysfunction and the so-called end stage occurs in 8% to 10% of patients with HCM and in ≤20% of patients carrying thin-filament mutations. 6 Of note, ranolazine prevented the disruption and disorganization of T-tubules, as evaluated with confocal microscopy using fluorescent membrane staining ( Figure 5 ), an effect that likely contributed to the preservation of LV diastolic and systolic function.
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Ranolazine Treatment Prevents the Development of Arrhythmogenic Substrates
Our results suggest that long-term ranolazine treatment is able to counteract the development of an arrhythmogenic substrate in the myocardium of mutant mice with HCM. Although we did not directly evaluate the frequency of ventricular ectopy nor the inducibility of arrhythmias in living animals, cardiomyocytes from treated mice showed a marked reduction in frequency of Ca 2+ waves and spontaneous Ca 2+ transients during pauses, both at baseline and during challenge with isoproterenol. Likewise, spontaneous contractions in intact trabeculae from R92Q-RAN mice were nearly absent, while they occurred with relatively high frequency in vehicle-treated mice. The reduction of Ca 2+ -dependent arrhythmogenesis is likely subtended by the normalization of intracellular Ca 2+ handling by ranolazine, 10 although other factors, such as the prevention of transcriptional changes in ion channel genes, such as I to , may have contributed to the effect of the treatment (Table  IV in the Data Supplement). CaMKII can acutely regulate ion channels (I Na , I Ca , I K ) and Ca 2+ -handling proteins (RyR, IP3R, PLB), directly contributing to triggered arrhythmias (such as Early After-depolarizations and Delayed After-depolarizations). 43 Reduction of CaMKII activity by ranolazine treatment is likely to have contributed to the reduction of arrhythmias in treated R92Q mice. Finally, at the whole heart level, the reduction of cellular arrhythmic triggers is paralleled by a reduced intramyocardial fibrosis (a substrate for re-entry circuits), potentially lowering the risk of sustained ventricular arrhythmias. Ranolazine Prevents Cardiac Remodeling in HCM
Mechanisms Underlying the Efficacy of Ranolazine in R92Q-TnT Mice
The CaMKII-I NaL vicious cycle is a well-established phenomenon occurring in several cardiac diseases, including human HCM. In brief, increased I NaL leads to intracellular Na + overload, which impairs NCX-mediated extrusion of Ca 2+ , thus, contributing to Ca 2+ overload, which in turn potentiates CaMKII activity via calmodulin binding 13 ; in addition, Na + overload increases mitochondrial reactive oxygen species production and oxidation of CaMKII, leading to its constitutive activation. 44 The hyperfunctional CaMKII, via direct phosphorylation of NaV1.5 Na + channels, contributes to further increase in I NaL . 34 Although increased I NaL is never the primary cause of disease (with the exception of LQT3), it is a common feature of cardiac cell remodeling in several conditions, including mice carrying the R92Q TnT mutation (Figure 1) . Inhibition of I NaL is likely to thwart the establishment of the aforementioned vicious cycle, leading to a sustained reduction of CaMKII activity. Indeed, we have found that the degree of CaMKII autophosphorylation at Thr286 site is markedly increased in untreated R92Q mice, while it is undistinguishable from WT in ranolazine-treated mutants ( Figure 6G and 6H). Prolonged CaMKII hyperactivity in cardiac diseases is associated with changes of gene expression program that ultimately contribute to drive myocardial remodeling both at cellular level (hypertrophy, changes of cellular substructures, expression of ion channels, and EC-coupling proteins) and at extracellular level (intramyocardial fibrosis). Activated CaMKII can migrate to the nucleus and phosphorylate hystone deacetylase (HDAC4), thus, relieving the inhibition of the transcription of myocyte enhancer factor-2 (MEF2)-controlled genes. 45 In addition, Ca-activated calmodulin may also bind to calcineurin and dephosphorylate Nuclear factor of activated T cells (NFAT), which in turn may increase GATA-dependent transcription. 43 Interestingly, MEF2 and GATA-controlled genes are involved in the development of pathological cardiomyocyte hypertrophy, as well as in the often associated extracellular matrix remodeling and fibrosis. Therefore, the reduction of CaMKII activity after I NaL inhibition in ranolazine-treated R92Q mice is likely to be the main mechanism that prevented disease-related structural and functional myocardial changes in treated mice.
In a recent work by Flenner et al, 46 mice carrying an MyBPC mutation related to HCM were treated with ranolazine, and most of the observed effects of the drug in that model were found to be related with a significant inhibition of β-adrenergic receptors. Ranolazine has a significant β-blocking effect when the plasma concentration is >13 μmol/L, 47 much higher than the clinically relevant concentration range (from 2 to 5 μmol/L). Indeed, Flenner et al 46 reached very high plasma ranolazine concentrations in their treated mice (>20 μmol/L), so a β-blocking effect observed with their protocol is expected, but scarcely clinically relevant. In our ranolazine-treated male mice, plasma ranolazine concentration ranged from 2.5 to 5.5 μmol/L (average 4 μmol/L). Moreover, they do not show lower heart rate and blood pressure when compared with vehicle-treated mice (Table II in the Data Supplement) . Furthermore, phosphorylation of protein kinase A targets is not reduced in the hearts from treated versus untreated R92Q mice ( Figure IV in the Data Supplement). Therefore, we can reliably exclude that a significant β-blocking action plays a role in determining the effects of ranolazine in R92Q-TnT mice. Finally, despite their widespread use in HCM patients, β-blockers have never been proven to be capable of slowing or preventing the development or progression of disease in murine HCM models or in patients 3,7 on longterm administration.
Implications for Clinical Management
Taken together, our data support the role of ranolazine or other I NaL inhibitors to prevent, delay, or attenuate the onset and severity of disease in subjects carrying mutations associated with severe forms of HCM. 5, 6 The feasibility of preventive treatment strategies in young HCM mutation carriers has been recently ascertained by Ho et al, 12 who recently completed a trial with diltiazem and are currently performing a trial with valsartan in this group of patients (VANISH Trial [Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM]).
Although the present results support the use of ranolazine in subjects carrying high-risk thin-filament mutations, whether its efficacy extends to other genotypes remains to be determined. A recent study by Flenner et al 46 showed that a 6-month treatment with ranolazine did not reduce cardiac hypertrophy or diastolic dysfunction in an MyBPC-mutant HCM mouse model. The lack of effects of ranolazine in that work stems from the absence of a significant increase of I NaL in cardiomyocytes from MyBPC-mutant mice as compared with WT littermates, 46 at variance with the R92Q-TnT model. In human cardiomyocytes from adult patients with HCM, however, we previously showed that similar electric abnormalities (including increased I NaL ) are also present in cardiomyocytes from patients carrying MyBPC mutations, 10 and the benefits of acute ranolazine administration seemed independent from the presence of a specific mutation. The cardiac pathological phenotype of the MyBPC mouse model in the work by Flenner et al 46 was rather mild, with slight diastolic dysfunction, minimal LV hypertrophy, and little cellular abnormalities, 33 and provided a lesser approximation of advanced human disease as observed in patient samples, 10 as compared with the R92Q model. Moreover, Flenner et al started treatment in young adult mice of 2 months of age when disease phenotype was already fully expressed, 33 while we initiated treatment right after birth, before HCM phenotypic expression. This suggests that initiation of treatment before the onset of cardiac pathological changes is preferable to achieve a disease-modifying effect in HCM. Indeed, other supposedly disease-modifying agents, such as sartans or statins, have failed to reduce established hypertrophy and fibrosis in adult HCM patients with overt disease, 48 while early treatment of young mutation carriers with diltiazem has somewhat succeeded. 12 Based on the results of the present work, we think that it would be essential for a preventive treatment with I NaL inhibitors to be started before the onset of pathological phenotype, that is, during early to late childhood (5-14 years). We do not think that initiation of treatment at birth in humans would be necessary to achieve the expected results. The reason why we Ranolazine Prevents Cardiac Remodeling in HCM decided to treat cTnT-R92Q mice since birth is because pathological cardiac changes (including increased I NaL ) start developing early in R92Q mice and are mostly preset at 1 month of age. Because it was impossible for us to define the exact time of the onset of disease-related changes during the first month of life, we decided to initiate treatment right after birth. Comparing the development of HCM in transgenic mice with that occurring in human children and young adults is nearly impossible, given the remarkable differences in the physiology of heart maturation and growth. At birth, the functional maturity of cardiomyocytes in the mouse heart is relatively higher than that in newborn humans. 49 From a translational standpoint, we think that starting treatment in a newborn mouse would be the equivalent of starting treatment in a 6-year-old child. This strategy could be feasible in individuals carrying high-risk mutations, such as thin-filament mutations, identified in familial screening programs.
Our work highlights the role of ranolazine as an agent to treat young carriers of high-risk mutations (eg, thinfilament mutations or aggressive MYH7 mutations). These subjects have a relatively high risk of lethal arrhythmias during adolescence and early adulthood and an increased likelihood of developing terminal heart failure later in life, with either hypocontractile or restrictive phenotype. 5, 6 These patients are currently orphan of effective therapies because current strategies are unable to prevent arrhythmias or heart failure; thus, early prevention of phenotype development is the only possible therapeutic option.
Ranolazine is already available in the clinic for angina treatment and has been recently assessed in patients with symptomatic HCM (RESTYLE-HCM study [Ranolazine in Symptomatic Hypertrophic Cardiomyopathy]; EudraCT number, 2011-004507-20); in addition, eleclazine, a novel selective I NaL inhibitor with improved efficacy and safety, is currently under clinical development and is being trialed in HCM patients (LIBERTY-HCM study [Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy]; EudraCT number, 2013-004429-97). 50 The results of these studies may provide clinical evidence in support to our observations and answer the question whether the strategy of I NaL inhibition is effective in ameliorating the clinical profile of adult patients with overt HCM. Whatever the results of these studies, however, the present work strongly supports a rationale for ranolazine or other I NaL inhibitors as promising preventive therapy in carriers of HCM mutations at risk of developing a severe form of the disease.
